The Role of Inflammatory Markers in Assessing Stroke Risk in Diabetes

Diabetes mellitus, particularly type 2 diabetes (T2D), creates a profound burden of cardiovascular disease, with ischemic stroke representing a leading cause of disability and death. Globally, an estimated 537 million adults live with diabetes, and the lifetime risk of stroke in this population is nearly double that of individuals without the condition. Traditional risk factors—hypertension, dyslipidemia, and smoking—only partially account for this heightened risk. The metabolic abnormalities inherent in diabetes, including chronic hyperglycemia, insulin resistance, and dyslipidemia, actively fuel a state of low-grade systemic inflammation. This inflammatory milieu is a primary driver of atherosclerosis, from initial endothelial dysfunction to acute plaque rupture and thromboembolic events. Inflammatory markers, measurable in peripheral blood, provide a window into this pathological process, offering predictive value beyond conventional risk assessment tools. Understanding the role of these biomarkers is essential for refining stroke risk stratification and guiding targeted therapeutic interventions in patients with diabetes.

The link between diabetes and stroke is fundamentally mediated by accelerated atherosclerosis driven by metabolic stress and chronic inflammation. Hyperglycemia initiates a cascade of detrimental cellular events, including the formation of advanced glycation end-products (AGEs). When AGEs bind to their receptor (RAGE) on endothelial cells, they activate the nuclear factor kappa-B (NF-κB) pathway, a master regulator of pro-inflammatory gene expression. This activation leads to the production of adhesion molecules (such as VCAM-1 and ICAM-1), chemokines, and cytokines, including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). Simultaneously, insulin resistance in T2D impairs the anti-inflammatory and anti-atherogenic actions of insulin in the vasculature. The NLRP3 inflammasome, a critical intracellular complex, plays a central role in sensing metabolic stress and cleaving pro-IL-1β into its active, inflammatory form.

This inflammatory cascade promotes the recruitment of monocytes into the arterial wall, where they differentiate into macrophages. These macrophages ingest oxidized low-density lipoprotein (LDL), becoming foam cells that form the core of atherosclerotic plaques. In an inflammatory environment, smooth muscle cell proliferation and collagen deposition are altered, creating a thin-cap fibroatheroma that is prone to rupture. Plaque rupture exposes thrombogenic material to the bloodstream, leading to platelet activation, coagulation, and thromboembolic occlusion of cerebral arteries. This process explains why elevated levels of systemic inflammatory markers correlate strongly with stroke incidence in diabetic populations, as they reflect both the burden of atherosclerotic disease and the instability of existing plaques.

Key Inflammatory Biomarkers and Their Prognostic Value

Numerous inflammatory biomarkers have been investigated for their ability to predict stroke risk in patients with diabetes. These markers vary in their biological specificity, clinical availability, and strength of evidence. The most extensively studied and clinically applicable markers include high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), alongside broader indicators such as fibrinogen.

High-Sensitivity C-Reactive Protein (hs-CRP)

hs-CRP is an acute-phase reactant synthesized predominantly by the liver under the stimulation of IL-6. It is the most widely validated inflammatory biomarker for cardiovascular risk prediction. Elevated hs-CRP levels (typically >2 mg/L) have been consistently associated with an increased risk of incident stroke, independent of LDL cholesterol and traditional risk factors. In patients with diabetes, hs-CRP retains significant predictive power. A meta-analysis of prospective studies demonstrated that individuals with diabetes and hs-CRP levels in the highest quartile had a 70% higher risk of stroke compared to those in the lowest quartile. The clinical utility of hs-CRP was highlighted in the JUPITER trial, which showed that rosuvastatin significantly reduced major cardiovascular events, including stroke, in healthy individuals with elevated hs-CRP and normal LDL levels. In a pre-specified analysis of participants with diabetes, the magnitude of benefit was substantial, supporting the concept that targeting inflammation yields cardiovascular dividends. The American Heart Association (AHA) and the Centers for Disease Control and Prevention (CDC) have issued a scientific statement supporting the use of hs-CRP for risk stratification in intermediate-risk patients, a category that includes many with diabetes. Clinically, hs-CRP levels are categorized as low risk (<1 mg/L), average risk (1–3 mg/L), and high risk (>3 mg/L), though values above 10 mg/L often reflect acute infection or other inflammatory conditions and require cautious interpretation. For a comprehensive overview of inflammatory markers in cardiovascular disease, refer to the AHA/CDC Scientific Statement on Markers of Inflammation and Cardiovascular Disease.

Interleukin-6 (IL-6)

IL-6 is a central pleiotropic cytokine that orchestrates the acute-phase response and is a key mediator of chronic inflammation. It is produced by multiple cell types, including activated macrophages, adipocytes, and endothelial cells. IL-6 is the primary stimulus for hepatic CRP production, and its levels are often closely correlated. Mendelian randomization studies have suggested a potential causal role for IL-6 signaling in cardiovascular disease, making it an attractive biomarker and therapeutic target. Elevated IL-6 levels are associated with increased stroke risk in patients with diabetes, independent of CRP. The RESCUE trial demonstrated that ziltivekimab, a monoclonal antibody targeting the IL-6 ligand, significantly reduced biomarkers of inflammation (including hs-CRP, fibrinogen, and serum amyloid A) in patients with chronic kidney disease. These results have spurred interest in the ongoing ZEUS trial, which is evaluating the cardiovascular efficacy of ziltivekimab in a broader high-risk population. IL-6 may offer additive predictive value when used in conjunction with hs-CRP, identifying individuals with a particularly high inflammatory burden and residual risk.

Tumor Necrosis Factor-Alpha (TNF-α)

TNF-α is a major pro-inflammatory cytokine that contributes to systemic inflammation and insulin resistance. It is overexpressed in the adipose tissue of obese individuals and plays a direct role in promoting vascular inflammation, endothelial dysfunction, and the expression of adhesion molecules. While TNF-α is a validated target in autoimmune diseases like rheumatoid arthritis (with agents such as infliximab and adalimumab), its utility as a stroke risk biomarker in diabetes is less established than hs-CRP or IL-6. Some studies have shown associations between elevated TNF-α levels and incident cardiovascular events, including stroke, but the data are less consistent due to measurement variability and its short half-life. Its measurement remains largely confined to research settings.

Fibrinogen and Other Markers

Fibrinogen is a glycoprotein synthesized by the liver that plays a dual role in hemostasis and inflammation. As an acute-phase reactant, its levels rise in response to IL-6 stimulation. Elevated fibrinogen increases blood viscosity, promotes platelet aggregation, and contributes to fibrin formation, directly enhancing thrombotic risk. The Fibrinogen Studies Collaboration, a large-scale meta-analysis of individual participant data, confirmed a strong, independent association between fibrinogen levels and coronary heart disease, stroke, and vascular mortality. Fibrinogen is a widely available and low-cost test, making it a practical adjunct for risk assessment in resource-limited settings. Other markers, such as lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO), and adipokines (e.g., adiponectin and leptin), are also under investigation. Lp-PLA2 is a vascular-specific inflammatory enzyme produced by macrophages in atherosclerotic plaques, and its activity can be measured with the PLAC test. The FDA has approved Lp-PLA2 testing for risk stratification, and elevated levels are associated with stroke independent of other risk factors.

Clinical Utility in Risk Stratification

Integrating inflammatory markers into clinical practice requires understanding their additive value beyond traditional risk factors. The American Diabetes Association (ADA) Standards of Medical Care in Diabetes acknowledges that measuring hs-CRP can help identify patients at elevated risk for cardiovascular disease. The ASCVD Risk Estimator Plus, a tool endorsed by the American College of Cardiology and the AHA, includes an option to incorporate hs-CRP to refine risk prediction. A patient with diabetes and an intermediate 10-year risk (e.g., 7.5–20%) who has an hs-CRP level above 2 mg/L may be reclassified into a higher risk category, prompting more intensive preventive therapy.

The concept of "residual inflammatory risk" is clinically useful. A patient may achieve excellent LDL cholesterol lowering (<70 mg/dL) and adequate glycemic control (HbA1c <7%) but still harbor elevated inflammatory markers (hs-CRP >2 mg/L). This patient remains at substantial risk for stroke and cardiovascular events. Identifying this phenotype is important because it opens the door to additional therapeutic options. It is essential to measure hs-CRP or fibrinogen when the patient is metabolically stable, avoiding measurement during acute infections, recent surgery, or active inflammatory disease (e.g., rheumatoid arthritis flare), as these conditions can dramatically elevate levels and confound interpretation.

Therapeutic Implications: Lowering Inflammation to Prevent Stroke

The identification of elevated inflammatory markers in a patient with diabetes should trigger a comprehensive review of preventive strategies, encompassing both lifestyle interventions and pharmacotherapy.

Lifestyle and Metabolic Interventions

Lifestyle modification is a foundational approach to reducing both diabetes progression and inflammation. Weight loss of 5–10% in overweight or obese individuals has been shown to significantly reduce hs-CRP and IL-6 levels. Dietary patterns such as the Mediterranean diet, rich in monounsaturated fats, polyphenols, and omega-3 fatty acids, possess inherent anti-inflammatory properties. Regular aerobic exercise (150 minutes per week of moderate activity) also reduces systemic inflammation, independent of weight loss. Smoking cessation leads to rapid declines in multiple inflammatory markers, including CRP, fibrinogen, and leukocyte count.

Pharmacotherapy

Multiple classes of medications used in diabetes management have demonstrated significant anti-inflammatory effects.

  • Statins: Statins are the cornerstone of dyslipidemia management and exhibit powerful pleiotropic anti-inflammatory effects. The JUPITER trial explicitly demonstrated the benefit of statin therapy in individuals selected for elevated hs-CRP. In patients with diabetes, statins reduce hs-CRP levels by approximately 15–30%, and the clinical benefit of statins is greatest in those who achieve both low LDL-C and low hs-CRP.
  • Metformin: Beyond its glucose-lowering effects, metformin activates AMP-activated protein kinase (AMPK), which suppresses NF-κB signaling and reduces the production of pro-inflammatory cytokines. Metformin therapy is associated with lower hs-CRP levels in patients with T2D.
  • GLP-1 Receptor Agonists (GLP-1 RAs) and SGLT2 Inhibitors: Major cardiovascular outcome trials (CVOTs) with agents like liraglutide, semaglutide, and empagliflozin have shown significant reductions in major adverse cardiovascular events, including stroke. These benefits are partly attributable to favorable effects on inflammation, oxidative stress, and endothelial function. GLP-1 RAs have been shown to reduce hs-CRP and improve markers of endothelial health.
  • Pioglitazone: This thiazolidinedione (TZD) is a PPAR-γ agonist that has well-documented anti-inflammatory effects, reducing hs-CRP levels and carotid intima-media thickness. The IRIS trial demonstrated that pioglitazone reduced the risk of stroke and myocardial infarction in patients with insulin resistance and a recent history of stroke or transient ischemic attack (TIA).

Targeted Anti-Inflammatory Therapy

The CANTOS trial was a landmark study that provided definitive proof of the inflammatory hypothesis of atherothrombosis. In this trial, canakinumab—a monoclonal antibody neutralizing IL-1β—reduced major cardiovascular events independent of LDL lowering in patients with a history of myocardial infarction and high hs-CRP (>2 mg/L). The trial also showed a reduction in incident stroke. Although canakinumab is not approved for cardiovascular prevention due to its cost and risk of fatal infections, it validated the concept that directly targeting inflammation reduces vascular risk. The CANTOS trial results opened the door for repurposing or developing safer anti-inflammatory agents.

Colchicine, a widely available and inexpensive anti-inflammatory drug, has emerged as a promising option. The COLCOT and LoDoCo2 trials demonstrated that low-dose colchicine (0.5 mg daily) significantly reduced cardiovascular events in patients with chronic coronary artery disease. While the event rates of stroke were not the primary focus, these trials provide compelling evidence that targeting inflammation with colchicine is effective. Colchicine inhibits tubulin polymerization and the NLRP3 inflammasome, reducing IL-1β and IL-6 production.

Future Directions and Emerging Markers

The field is moving toward more precise, personalized risk assessment. Multi-marker panels combining hs-CRP, IL-6, fibrinogen, and adiponectin may offer superior predictive accuracy compared to any single marker, though practical and cost-effectiveness questions remain. Proteomics and metabolomics are identifying novel inflammatory mediators and pathways involved in diabetes-related vascular disease. Genetic risk scores (PRS) for inflammatory traits, such as the IL-6 receptor genetic variant rs2228145, may help identify individuals who are genetically predisposed to inflammation and who may derive enhanced benefit from specific anti-inflammatory therapies. Clinical trials are ongoing to evaluate agents like ziltivekimab (targeting IL-6) and several oral NLRP3 inhibitors in diverse patient populations. The integration of these tools into routine care will depend on demonstrating that their use improves clinical outcomes in a cost-effective manner.

Conclusion: Integrating Inflammation into Clinical Practice

In patients with diabetes, the assessment of inflammatory markers provides a critical layer of risk information that complements traditional factors like LDL cholesterol and HbA1c. While hs-CRP remains the most clinically accessible and validated biomarker, emerging measures such as IL-6 and fibrinogen offer deeper mechanistic insights. Identifying and targeting residual inflammatory risk represents a major frontier in preventive cardiology and neurology. Lifestyle interventions, optimized glucose management, statin therapy, and newer agents like GLP-1 receptor agonists and colchicine offer actionable strategies to mitigate this risk. As the therapeutic arsenal expands to include specific anti-inflammatory agents, the measurement of these markers will become increasingly essential for delivering precise, personalized stroke prevention strategies in the growing population of patients with diabetes. The routine integration of inflammatory profiling into clinical practice is a practical and powerful step toward reducing the global burden of stroke.